Is MRNA or MGX more profitable?

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Metagenomi -384.61% -51.23% -36.62%

Does the media prefer MRNA or MGX?

In the previous week, Moderna had 23 more articles in the media than Metagenomi. MarketBeat recorded 26 mentions for Moderna and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.62 beat Moderna's score of 0.53 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UNCY or MGX?

In the previous week, Metagenomi had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat Metagenomi's score of 0.62 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TNXP or MGX?

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.62 beat Tonix Pharmaceuticals' score of 0.27 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARTV or MGX?

In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 3 mentions for Metagenomi. Artiva Biotherapeutics' average media sentiment score of 0.97 beat Metagenomi's score of 0.62 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MGX or KRRO?

Metagenomi has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $25.21M 1.95 -$87.87M -$2.30 N/A Korro Bio $6.39M 23.99 -$117.26M -$11.67 N/A

Is MGX or KRRO more profitable?

Metagenomi has a net margin of -384.61% compared to Korro Bio's net margin of -1,834.48%. Metagenomi's return on equity of -51.23% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% Korro Bio -1,834.48% -117.86% -71.04%

Does the media refer more to MGX or KRRO?

In the previous week, Korro Bio had 14 more articles in the media than Metagenomi. MarketBeat recorded 17 mentions for Korro Bio and 3 mentions for Metagenomi. Korro Bio's average media sentiment score of 0.88 beat Metagenomi's score of 0.62 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Metagenomi (MGX) Competitors

$1.30 -0.03 (-1.88%)

As of 01:10 PM Eastern

Compare

MGX vs. MRNA, UNCY, TNXP, ARTV, and KRRO

Should you buy Metagenomi stock or one of its competitors? MarketBeat compares Metagenomi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Metagenomi include Moderna (MRNA), Unicycive Therapeutics (UNCY), Tonix Pharmaceuticals (TNXP), Artiva Biotherapeutics (ARTV), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry.

How does Metagenomi compare to Moderna?

Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.68	-$2.82B	-$8.15	N/A
Metagenomi	$25.21M	1.95	-$87.87M	-$2.30	N/A

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Moderna had 23 more articles in the media than Metagenomi. MarketBeat recorded 26 mentions for Moderna and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.62 beat Moderna's score of 0.53 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Positive
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna presently has a consensus target price of $35.73, indicating a potential downside of 24.63%. Metagenomi has a consensus target price of $9.00, indicating a potential upside of 589.66%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Metagenomi beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Unicycive Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Metagenomi	-384.61%	-51.23%	-36.62%

Unicycive Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

In the previous week, Metagenomi had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat Metagenomi's score of 0.62 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics presently has a consensus target price of $24.75, indicating a potential upside of 241.85%. Metagenomi has a consensus target price of $9.00, indicating a potential upside of 589.66%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Unicycive Therapeutics has higher earnings, but lower revenue than Metagenomi. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$2.21	N/A
Metagenomi	$25.21M	1.95	-$87.87M	-$2.30	N/A

Summary

Metagenomi beats Unicycive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Metagenomi has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$17.56M	10.30	-$124.02M	-$14.36	N/A
Metagenomi	$25.21M	1.95	-$87.87M	-$2.30	N/A

Tonix Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Metagenomi has a net margin of -384.61% compared to Tonix Pharmaceuticals' net margin of -839.52%. Metagenomi's return on equity of -51.23% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.62 beat Tonix Pharmaceuticals' score of 0.27 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tonix Pharmaceuticals presently has a consensus target price of $22.00, indicating a potential upside of 94.00%. Metagenomi has a consensus target price of $9.00, indicating a potential upside of 589.66%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Metagenomi beats Tonix Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Artiva Biotherapeutics has higher earnings, but lower revenue than Metagenomi. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	696.12	-$83.86M	-$3.54	N/A
Metagenomi	$25.21M	1.95	-$87.87M	-$2.30	N/A

Artiva Biotherapeutics has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 3 mentions for Metagenomi. Artiva Biotherapeutics' average media sentiment score of 0.97 beat Metagenomi's score of 0.62 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 453.98%. Metagenomi has a consensus price target of $9.00, indicating a potential upside of 589.66%. Given Metagenomi's higher probable upside, analysts plainly believe Metagenomi is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Artiva Biotherapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Metagenomi	-384.61%	-51.23%	-36.62%

Summary

Artiva Biotherapeutics beats Metagenomi on 8 of the 14 factors compared between the two stocks.

How does Metagenomi compare to Korro Bio?

Metagenomi (NASDAQ:MGX) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Metagenomi has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, meaning that its share price is 200% more volatile than the broader market.

13.2% of Korro Bio shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Korro Bio had 14 more articles in the media than Metagenomi. MarketBeat recorded 17 mentions for Korro Bio and 3 mentions for Metagenomi. Korro Bio's average media sentiment score of 0.88 beat Metagenomi's score of 0.62 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Metagenomi currently has a consensus target price of $9.00, suggesting a potential upside of 589.66%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 57.24%. Given Metagenomi's higher possible upside, research analysts plainly believe Metagenomi is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Metagenomi has a net margin of -384.61% compared to Korro Bio's net margin of -1,834.48%. Metagenomi's return on equity of -51.23% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Metagenomi has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.95	-$87.87M	-$2.30	N/A
Korro Bio	$6.39M	23.99	-$117.26M	-$11.67	N/A

Summary

Metagenomi beats Korro Bio on 9 of the 17 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.13M	$2.90B	$6.26B	$12.40B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-0.57	17.65	22.37	24.16
Price / Sales	1.95	480.77	547.57	124.65
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	0.31	3.84	9.79	6.69
Net Income	-$87.87M	$75.85M	$3.56B	$336.98M
7 Day Performance	-3.33%	-2.32%	-1.27%	0.45%
1 Month Performance	-6.12%	20.70%	3.58%	4.95%
1 Year Performance	-26.27%	21.18%	27.13%	34.01%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	2.5582 of 5 stars	$1.31 -1.9%	$9.00 +589.7%	-24.4%	$49.13M	$25.21M	N/A	236
MRNA Moderna	1.5144 of 5 stars	$44.65 -5.4%	$35.73 -20.0%	+68.7%	$18.72B	$2.20B	N/A	4,700	Trending News
UNCY Unicycive Therapeutics	3.9369 of 5 stars	$7.34 -0.5%	$24.00 +227.0%	+9.1%	$197.05M	$680K	N/A	9	Analyst Forecast
TNXP Tonix Pharmaceuticals	3.9119 of 5 stars	$11.86 -3.9%	$22.00 +85.6%	-69.2%	$196.55M	$13.11M	N/A	50
ARTV Artiva Biotherapeutics	4.3771 of 5 stars	$6.89 -13.1%	$39.00 +466.1%	+254.1%	$196.01M	N/A	N/A	81	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, UNCY, TNXP, ARTV, and KRRO

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to Unicycive Therapeutics?

Summary

How does Metagenomi compare to Tonix Pharmaceuticals?

Summary

How does Metagenomi compare to Artiva Biotherapeutics?

Summary

How does Metagenomi compare to Korro Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, UNCY, TNXP, ARTV, and KRRO

How does Metagenomi compare to Moderna?

Which has higher earnings and valuation, MRNA or MGX?

Which has more risk & volatility, MRNA or MGX?

Is MRNA or MGX more profitable?

Does the media prefer MRNA or MGX?

Do analysts rate MRNA or MGX?

Do insiders and institutionals hold more shares of MRNA or MGX?

Summary

How does Metagenomi compare to Unicycive Therapeutics?

Do institutionals and insiders believe in UNCY or MGX?

Is UNCY or MGX more profitable?

Which has more volatility & risk, UNCY or MGX?

Does the media favor UNCY or MGX?

Do analysts rate UNCY or MGX?

Which has preferable valuation and earnings, UNCY or MGX?

Summary

How does Metagenomi compare to Tonix Pharmaceuticals?

Do institutionals & insiders believe in TNXP or MGX?

Which has preferable earnings and valuation, TNXP or MGX?

Which has more volatility and risk, TNXP or MGX?

Is TNXP or MGX more profitable?

Does the media prefer TNXP or MGX?

Do analysts recommend TNXP or MGX?

Summary

How does Metagenomi compare to Artiva Biotherapeutics?

Which has better earnings & valuation, ARTV or MGX?

Which has more volatility and risk, ARTV or MGX?

Does the media prefer ARTV or MGX?

Do analysts prefer ARTV or MGX?

Is ARTV or MGX more profitable?

Summary

How does Metagenomi compare to Korro Bio?

Which has more volatility & risk, MGX or KRRO?

Do institutionals and insiders have more ownership in MGX or KRRO?

Does the media refer more to MGX or KRRO?

Do analysts recommend MGX or KRRO?

Is MGX or KRRO more profitable?

Which has better valuation and earnings, MGX or KRRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools